Table 5.
Relative risk of second primary cancer by type of first primary cancer and follow-up interval, Queensland, 1982-2006
| Follow-up interval | ||||||||
|---|---|---|---|---|---|---|---|---|
| 2 months to less than 1 year | 1 year to less than 5 years | 5 years to less than 10 years | 10 years or longer | |||||
| First primary cancer | Obs. |
SIR (95% CI) |
Obs. |
SIR (95% CI) |
Obs. |
SIR (95% CI) |
Obs. |
SIR (95% CI) |
| Head and neck | 164 |
1.67 (1.42-1.95) |
731 |
2.00 (1.86-2.15) |
651 |
2.10 (1.94-2.26) |
443 |
1.89 (1.72-2.08) |
| Oesophagus | 22 | 1.22 (0.77-1.85) |
42 | 1.31 (0.95-1.77) |
32 |
1.76 (1.20-2.48) |
9 | 1.11 (0.51-2.10) |
| Stomach | 36 | 0.97 (0.68-1.35) |
75 | 0.95 (0.74-1.18) |
55 | 1.04 (0.78-1.35) |
40 | 0.99 (0.71-1.35) |
| Colorectal | 310 | 1.03 (0.92-1.16) |
1,131 |
1.07 (1.01-1.13) |
912 |
1.11 (1.04-1.18) |
693 |
1.14 (1.06-1.23) |
| Pancreas | 14 | 0.74 (0.40-1.24) |
20 | 1.01 (0.62-1.57) |
15 | 0.99 (0.55-1.64) |
-- | -- |
| Lung | 147 | 1.06 (0.89-1.24) |
312 |
1.46 (1.30-1.63) |
183 |
1.71 (1.47-1.98) |
87 |
1.35 (1.08-1.67) |
| Melanoma | 458 |
2.15 (1.95-2.35) |
1,798 |
1.92 (1.84-2.02) |
1,553 |
1.80 (1.71-1.89) |
1,283 |
1.63 (1.55-1.73) |
| Breast - female | 194 | 1.02 (0.88-1.18) |
1,020 |
1.25 (1.17-1.33) |
1,019 |
1.44 (1.35-1.53) |
729 |
1.36 (1.26-1.46) |
| Cervix | 33 |
2.13 (1.46-2.99) |
89 |
1.46 (1.18-1.80) |
89 |
1.43 (1.15-1.76) |
89 | 1.09 (0.87-1.34) |
| Uterus | 29 | 1.03 (0.69-1.48) |
134 | 1.15 (0.96-1.36) |
147 |
1.36 (1.15-1.60) |
99 | 1.00 (0.81-1.21) |
| Ovary | 22 | 1.22 (0.77-1.85) |
54 | 1.04 (0.78-1.35) |
46 | 1.18 (0.86-1.57) |
42 | 1.11 (0.80-1.50) |
| Prostate | 344 |
0.81 (0.73-0.90) |
1,368 |
0.84 (0.80-0.89) |
988 |
0.88 (0.82-0.93) |
306 |
0.66 (0.59-0.74) |
| Kidney | 115 |
2.45 (2.02-2.94) |
254 |
1.57 (1.38-1.77) |
177 |
1.42 (1.22-1.65) |
109 |
1.35 (1.11-1.63) |
| Bladder | 249 |
2.40 (2.11-2.72) |
668 |
1.73 (1.61-1.87) |
477 |
1.61 (1.47-1.76) |
286 |
1.39 (1.23-1.56) |
| Brain & CNS | 6 | 0.60 (0.22-1.31) |
12 | 0.77 (0.40-1.34) |
18 | 1.44 (0.85-2.28) |
14 | 1.28 (0.70-2.15) |
| Thyroid | 18 | 1.65 (0.98-2.61) |
78 |
1.53 (1.21-1.91) |
63 | 1.21 (0.93-1.55) |
56 | 1.16 (0.87-1.50) |
| Non-Hodgkin lymphoma | 74 | 1.23 (0.97-1.55) |
262 |
1.31 (1.16-1.48) |
209 |
1.46 (1.27-1.67) |
144 |
1.49 (1.26-1.76) |
| Lymphoid leukaemia | 52 |
1.82 (1.36-2.39) |
156 |
1.40 (1.19-1.64) |
143 |
1.89 (1.59-2.23) |
71 |
1.78 (1.37-2.22) |
| Myeloid leukaemia | 27 |
1.59 (1.05-2.31) |
57 |
1.44 (1.09-1.87) |
28 | 1.40 (0.93-2.03) |
13 | 1.41 (0.75-2.41) |
| Myeloma/PCT | 18 | 0.76 (0.45-1.21) |
68 | 1.02 (0.79-1.29) |
36 | 1.26 (0.88-1.74) |
12 | 1.12 (0.58-1.95) |
| Other | 179 |
1.22 (1.05-1.42) |
595 |
1.35 (1.25-1.47) |
447 |
1.36 (1.24-1.49) |
332 |
1.33 (1.19-1.48) |
| All cancers combined | 2,511 |
1.32 (1.27-1.37) |
8,924 |
1.33 (1.31-1.36) |
7,286 |
1.39 (1.35-1.42) |
4,859 |
1.28 (1.24-1.31) |
Obs. = Observed number of second primary cancers; SIR = standardised incidence ratio; CI = confidence interval; CNS = central nervous system; PCT = plasma cell tumours. SIRs shown in normal bold font indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk. SIRs for pancreatic cancer for 5 years to less than 10 years after first diagnosis and 10 years or longer after first diagnosis have been combined due to less than 5 observed cases 10 years or longer after first diagnosis.